Targeted therapy for biliary tract carcinomas

VernacularTitle:胆道恶性肿瘤精准靶向治疗的研究进展
Author: Haimin WENG ¹ ; Jieer YING
Author Information

1. 浙江中医药大学第二临床医学院，杭州　310053
Keywords: Bile duct neoplasms; Targeted therapy; Cancer genes
From: Chinese Journal of Hepatobiliary Surgery 2022;28(12):955-960
CountryChina
Language:Chinese
Abstract: Biliary tract carcinomas (BTC) is characterized by high hetergenity. Despite being classified as rare cancers worldwide, the incidence of biliary tract carcinomas is increasing in China due to significant geographic variation. The current global needs for the treatment of BTC are far from being met, with advanced chemotherapy providing only limited survival benefits. Molecular targeted therapy, immunotherapy, and drug combination therapy have begun to flourish in recent years as its genetic characteristics are gradually revealed. This review summarized the therapeutically important targets of BTC, such as fibroblast growth factor receptor, isocitrate dehydrogenase and neurotrophic tyrosine receptor kinase as well as the advances in the research and development of their inhibitors, and prospects for precision targeted therapy for BTC.